Literature DB >> 28139194

Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systematic Sclerosis.

Chiara Capelli, Eleonora Zaccara, Paola Cipriani, Paola Di Benedetto, Wanda Maglione, Romina Andracco, Gabriele Di Luca, Francesca Pignataro, Roberto Giacomelli, Martino Introna, Claudio Vitali, Nicoletta Del Papa.   

Abstract

Mesenchymal stromal cells (MSCs) have received attention as an ideal source of regenerative cells because of their multipotent differentiation potential. Adipose tissue is an attractive source of MSCs. Recent studies have shown that autologous fat grafting may be effective in the treatment of systemic sclerosis (SSc), but no specific study exists that aimed at investigating whether adipose tissue-derived stromal cells (ADSCs) from SSc patients maintain normal phenotypic and functional characteristics. The purpose of the current study was to investigate whether ADSCs from patients with SSc (SSc-ADSCs) are phenotypically and functionally identical to those from healthy controls (HC-ADSCs). Adipose tissue samples were obtained from 10 patients with SSc and from 8 HCs. Both MSC populations were evaluated for their capacity to (a) express specific MSC surface antigens by flow cytometry analysis, (b) proliferate, (c) differentiate along the adipogenic and osteogenic lineages, (d) suppress in vitro lymphocyte proliferation induced by a mitogenic stimulus, and (e) support endothelial cell (EC) tube formation. ADSCs from SSc patients and HCs showed similar surface phenotype and multilineage differentiation capabilities. In PBMC proliferation inhibition assays, no significant differences were observed between SSc- and HC-ADSCs. Using ADSC/EC cocultures, both SSc- and HC-ADSCs improved tube formation by both HC- and SSc-ECs. This effect was enhanced under hypoxic conditions in all of the cocultures. SSc-ADSCs exhibited the same phenotypic pattern, proliferation and differentiation potentials, and immunosuppressive properties as those from HCs. The proangiogenic activity shown by SSc-ADSCs, namely, under hypoxic conditions, suggests that autologous ADSC grafting may represent a possible therapeutic option for SSc.

Entities:  

Mesh:

Year:  2017        PMID: 28139194      PMCID: PMC5657721          DOI: 10.3727/096368917X694822

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  61 in total

1.  Frontal linear scleroderma: long-term result in volumetric restoration of the fronto-orbital area by structural fat grafting.

Authors:  Giuseppe Consorti; Riccardo Tieghi; Luigi C Clauser
Journal:  J Craniofac Surg       Date:  2012-05       Impact factor: 1.046

2.  Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus.

Authors:  Dongyan Shi; Dandan Wang; Xia Li; Huayong Zhang; Nan Che; Zhimin Lu; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2012-05       Impact factor: 2.980

3.  Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro.

Authors:  C Bocelli-Tyndall; L Bracci; G Spagnoli; A Braccini; M Bouchenaki; R Ceredig; V Pistoia; I Martin; A Tyndall
Journal:  Rheumatology (Oxford)       Date:  2006-08-18       Impact factor: 7.580

4.  Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.

Authors:  P Cipriani; S Guiducci; I Miniati; M Cinelli; S Urbani; A Marrelli; V Dolo; A Pavan; R Saccardi; A Tyndall; R Giacomelli; M Matucci Cerinic
Journal:  Arthritis Rheum       Date:  2007-06

5.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

6.  Fat grafting to the hand in patients with Raynaud phenomenon: a novel therapeutic modality.

Authors:  Jonathan Bank; Sam M Fuller; Ginard I Henry; Lawrence S Zachary
Journal:  Plast Reconstr Surg       Date:  2014-05       Impact factor: 4.730

Review 7.  Immunomodulatory properties and therapeutic application of mesenchymal stem cells.

Authors:  M Shi; Z-W Liu; F-S Wang
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

8.  Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia.

Authors:  Yeon Kim; Hoe Kim; Hyun Cho; Yong Bae; Kuen Suh; Jin Jung
Journal:  Cell Physiol Biochem       Date:  2007

9.  Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT).

Authors:  Philippe Bourin; Bruce A Bunnell; Louis Casteilla; Massimo Dominici; Adam J Katz; Keith L March; Heinz Redl; J Peter Rubin; Kotaro Yoshimura; Jeffrey M Gimble
Journal:  Cytotherapy       Date:  2013-04-06       Impact factor: 5.414

10.  Human adipose stromal cells (ASC) for the regeneration of injured cartilage display genetic stability after in vitro culture expansion.

Authors:  Simona Neri; Philippe Bourin; Julie-Anne Peyrafitte; Luca Cattini; Andrea Facchini; Erminia Mariani
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

View more
  15 in total

Review 1.  Mesenchymal Stem Cell-Based Therapy as a New Approach for the Treatment of Systemic Sclerosis.

Authors:  Xiufen Zhuang; Xiao Hu; Shuren Zhang; Xingmin Li; Xiaoying Yuan; Yanhong Wu
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-15       Impact factor: 8.667

2.  Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1.

Authors:  Rebecca Lee; Nicoletta Del Papa; Martin Introna; Charles F Reese; Marina Zemskova; Michael Bonner; Gustavo Carmen-Lopez; Kristi Helke; Stanley Hoffman; Elena Tourkina
Journal:  J Scleroderma Relat Disord       Date:  2019-01-25

3.  How to Make Sense out of 75,000 Mesenchymal Stromal Cell Publications?

Authors:  Dina Mönch; Marlies E J Reinders; Marc H Dahlke; Martin J Hoogduijn
Journal:  Cells       Date:  2022-04-22       Impact factor: 7.666

Review 4.  Endothelial-to-mesenchymal transition in systemic sclerosis.

Authors:  P Cipriani; R Giacomelli; P Di Benedetto; P Ruscitti; O Berardicurti; M Vomero; L Navarini; V Dolo
Journal:  Clin Exp Immunol       Date:  2021-04-18       Impact factor: 5.732

5.  Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function.

Authors:  Guillaume Fonteneau; Claire Bony; Radjiv Goulabchand; Alexandre T J Maria; Alain Le Quellec; Sophie Rivière; Christian Jorgensen; Philippe Guilpain; Danièle Noël
Journal:  Front Immunol       Date:  2017-09-01       Impact factor: 7.561

6.  Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study.

Authors:  Nicoletta Del Papa; Gabriele Di Luca; Romina Andracco; Eleonora Zaccara; Wanda Maglione; Francesca Pignataro; Antonina Minniti; Claudio Vitali
Journal:  Arthritis Res Ther       Date:  2019-01-07       Impact factor: 5.156

7.  Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications.

Authors:  Mirko Manetti; Eloisa Romano; Irene Rosa; Bianca Saveria Fioretto; Emanuela Praino; Serena Guiducci; Florenzo Iannone; Lidia Ibba-Manneschi; Marco Matucci-Cerinic
Journal:  J Clin Med       Date:  2019-08-19       Impact factor: 4.241

Review 8.  Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?

Authors:  Pauline Rozier; Alexandre Maria; Radjiv Goulabchand; Christian Jorgensen; Philippe Guilpain; Danièle Noël
Journal:  Front Immunol       Date:  2018-12-14       Impact factor: 7.561

Review 9.  Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application.

Authors:  Simona Ceccarelli; Paola Pontecorvi; Eleni Anastasiadou; Claudio Napoli; Cinzia Marchese
Journal:  Front Cell Dev Biol       Date:  2020-04-17

Review 10.  Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.

Authors:  Juliette Peltzer; Marc Aletti; Nadira Frescaline; Elodie Busson; Jean-Jacques Lataillade; Christophe Martinaud
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.